Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma

Sponsor
Third Affiliated Hospital, Sun Yat-Sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05991856
Collaborator
(none)
45
1
131
0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to retrospectively and prospectively analyze the efficacy and safety of ultrasound-guided radiofrequency ablation and laparoscopic adrenalectomy in the treatment of aldosterone-producing adenoma (APA). It is planned to retrospectively collect 30 patients with adrenal radiofrequency ablation for APA and 15 patients with age - and sex-matched laparoscopic adrenalectomy for APA in our hospital from January 2020 to June 2024, and continue to follow up for 3 years.

Condition or Disease Intervention/Treatment Phase
  • Procedure: radiofrequency ablation
  • Procedure: laparoscopic adrenalectomy
  • Drug: Hypotensive Drugs

Detailed Description

Primary aldosteronism is the most common cause of secondary hypertension, and aldosterone-producing adenoma (APA) is a benign adrenal tumor, accounting for about 35% of primary aldosteronism. According to clinical guidelines, laparoscopic adrenalectomy is the preferred treatment for unilateral APA. Recently, radiofrequency ablation, as a new technique, has been applied to the treatment of APA. However, there are few relevant studies, the sample size is generally small, and basically belong to retrospective studies, lacking the comparison of long-term postoperative effects. Our hospital is the first to carry out ultrasound-guided radiofrequency ablation of APA in Guangdong, China, with satisfactory results. The purpose of this study is to retrospectively and prospectively analyze the efficacy and safety of ultrasound guided radiofrequency elimination and laparoscopic adrenalectomy in the treatment of APA. It is planned to retrospectively collect 30 patients with adrenal radiofrequency ablation for APA and 15 patients with age - and sex-matched laparoscopic adrenalectomy for APA in our hospital from January 2020 to June 2024, and continue to follow up for 3 years.

Study Design

Study Type:
Observational
Anticipated Enrollment :
45 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Resident Doctor, Master Degree Candidate
Actual Study Start Date :
Jan 1, 2020
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Dec 1, 2030

Arms and Interventions

Arm Intervention/Treatment
radiofrequency ablation

Patients with aldosterone-producing adenoma undergoing ultrasound-guided radiofrequency ablation

Procedure: radiofrequency ablation
The subjects is placed in a prone or lateral position under local anesthesia, and the electrodes are placed in the adrenal nodules under ultrasound guidance. A rapidly alternating radiofrequency current (300-500khz) generated around the electrode propagates through the adrenal nodules, causing resistance heating (Joule effect) and inducing cell death through coagulation necrosis. The choice of ablation time and frequency depends on the size, shape and location of the nodules within the adrenal gland.
Other Names:
  • RFA
  • Drug: Hypotensive Drugs
    All subjects in the study selected appropriate antihypertensive drugs based on factors such as blood pressure level.
    Other Names:
  • HD
  • laparoscopic adrenalectomy

    Patients with aldosterone-producing adenoma undergoing laparoscopic adrenalectomy

    Procedure: laparoscopic adrenalectomy
    The subjects was placed in a lateral position under general anesthesia. Using harmonic scalpel carefully separates the adrenal vessels and lates them. The adipose tissue around the adrenal gland is dissected carefully, the surrounding tissue is bluntly separated, and the adrenal gland is fully exposed and dissected. After adrenalectomy was completed, hemostasis was rechecked and specimens were removed.
    Other Names:
  • LA
  • Drug: Hypotensive Drugs
    All subjects in the study selected appropriate antihypertensive drugs based on factors such as blood pressure level.
    Other Names:
  • HD
  • Outcome Measures

    Primary Outcome Measures

    1. Blood pressure [Within 3 years]

      Effect of radiofrequency ablation and laparoscopic adrenalectomy on blood pressure levels in aldosterone-producing adenoma patients, including systolic and diastolic blood pressure(in millimeters of mercury, mmHg).

    2. Serum potassium [Within 3 years]

      Effect of radiofrequency ablation and laparoscopic adrenalectomy on serum potassium (mmol/L) levels in aldosterone-producing adenoma patient.

    3. Aldosterone [Within 3 years]

      The effects of radiofrequency ablation and laparoscopic adrenalectomy on aldosterone levels(ng/dl) in aldosterone-producing adenoma patients.

    4. ARR [Within 3 years]

      The effects of radiofrequency ablation and laparoscopic adrenalectomy on ARR (plasma aldosterone to renin activity ratio) in aldosterone-producing adenoma patients.

    5. Complications [Within 3 years]

      Intraoperative or postoperative complications of both types of surgery, including hypertensive crises, bleeding, and pancreatitis.

    6. PASO [Within 3 years]

      PASO(the Primary Aldosteronism Surgical Outcome) criteria were used to standardize the evaluation of outcomes of radiofrequency ablation and laparoscopic adrenalectomy, divided into clinical and biochemical outcomes, and the outcome grades were defined in terms of complete success, partial success, and unsuccessful.

    Secondary Outcome Measures

    1. Operation cost [Within 3 years]

      Comparison of the operation costs of radiofrequency ablation and laparoscopic adrenalectomy.

    2. Length of hospital stays [Within 3 years]

      Comparison of the hospital stays of radiofrequency ablation and laparoscopic adrenalectomy.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. APA was confirmed with unilateral lesions;

    2. Benign tumor without adrenal metastasis and endovascular tumor embolus;

    3. Receive ultrasound-guided adrenal RFA treatment or laparoscopic resection, and sign the informed consent for surgery;

    4. Age ≥ 18;

    5. Age ≥ 40 years old should meet the following criteria: blood potassium ≤3.5mmol/L; PAC≥20ng/dL; PRC≤5μIU/mL; A unilateral adrenal nodule of 10mm or more was completely normal on the opposite side.

    Exclusion Criteria:
    1. Bilateral adrenal diseases;

    2. Multiple adrenal tumors;

    3. Other adrenal diseases, such as adrenal hyperplasia, Cushing's syndrome, pheochromocytoma, etc.;

    4. Imaging suggests that the tumor may be difficult to reach;

    5. Imaging showed potential malignant adrenal tumor;

    6. Pregnant and/or planning a pregnancy;

    7. Refusing to participate in follow-up visits.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Third Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong China 510000

    Sponsors and Collaborators

    • Third Affiliated Hospital, Sun Yat-Sen University

    Investigators

    • Study Chair: Mengyin Cai, Dr, Third Affiliated Hospital, Sun Yat-Sen University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Xubin Yang, Dr., Third Affiliated Hospital, Sun Yat-Sen University
    ClinicalTrials.gov Identifier:
    NCT05991856
    Other Study ID Numbers:
    • HuanXu
    First Posted:
    Aug 15, 2023
    Last Update Posted:
    Aug 15, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Xubin Yang, Dr., Third Affiliated Hospital, Sun Yat-Sen University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 15, 2023